Logo image of SURG

SURGEPAYS INC (SURG) Stock Fundamental Analysis

NASDAQ:SURG - Nasdaq - US86882L2043 - Common Stock - Currency: USD

1.37  -0.03 (-2.14%)

After market: 1.36 -0.01 (-0.73%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SURG. SURG was compared to 22 industry peers in the Wireless Telecommunication Services industry. SURG scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SURG has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SURG has reported negative net income.
In the past year SURG has reported a negative cash flow from operations.
SURG had negative earnings in 4 of the past 5 years.
In multiple years SURG reported negative operating cash flow during the last 5 years.
SURG Yearly Net Income VS EBIT VS OCF VS FCFSURG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M

1.2 Ratios

SURG's Return On Assets of -55.17% is on the low side compared to the rest of the industry. SURG is outperformed by 95.24% of its industry peers.
Looking at the Return On Equity, with a value of -69.05%, SURG is doing worse than 85.71% of the companies in the same industry.
Industry RankSector Rank
ROA -55.17%
ROE -69.05%
ROIC N/A
ROA(3y)-7.37%
ROA(5y)-50.43%
ROE(3y)-107.11%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SURG Yearly ROA, ROE, ROICSURG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K

1.3 Margins

SURG's Gross Margin of 5.20% is on the low side compared to the rest of the industry. SURG is outperformed by 95.24% of its industry peers.
SURG's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for SURG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 5.2%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y78.16%
GM growth 5Y-10.03%
SURG Yearly Profit, Operating, Gross MarginsSURG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100

More info and screens

5

2. Health

2.1 Basic Checks

SURG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SURG has been increased compared to 1 year ago.
Compared to 5 years ago, SURG has more shares outstanding
SURG has a better debt/assets ratio than last year.
SURG Yearly Shares OutstandingSURG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M
SURG Yearly Total Debt VS Total AssetsSURG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

SURG has an Altman-Z score of 1.65. This is a bad value and indicates that SURG is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SURG (1.65) is better than 76.19% of its industry peers.
A Debt/Equity ratio of 0.08 indicates that SURG is not too dependend on debt financing.
SURG has a better Debt to Equity ratio (0.08) than 95.24% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z 1.65
ROIC/WACCN/A
WACC7.88%
SURG Yearly LT Debt VS Equity VS FCFSURG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 6.24 indicates that SURG has no problem at all paying its short term obligations.
The Current ratio of SURG (6.24) is better than 100.00% of its industry peers.
A Quick Ratio of 4.70 indicates that SURG has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 4.70, SURG belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.24
Quick Ratio 4.7
SURG Yearly Current Assets VS Current LiabilitesSURG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

3

3. Growth

3.1 Past

SURG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -177.93%.
SURG shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -40.73%.
The Revenue has been growing by 55.26% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-177.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-248.98%
Revenue 1Y (TTM)-40.73%
Revenue growth 3Y36.1%
Revenue growth 5Y55.26%
Sales Q2Q%-86.04%

3.2 Future

SURG is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -27.94% yearly.
SURG is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.49% yearly.
EPS Next Y-216.68%
EPS Next 2Y-45.58%
EPS Next 3Y-27.94%
EPS Next 5YN/A
Revenue Next Year-57%
Revenue Next 2Y-17.14%
Revenue Next 3Y6.49%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SURG Yearly Revenue VS EstimatesSURG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M
SURG Yearly EPS VS EstimatesSURG Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 1 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SURG. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SURG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SURG Price Earnings VS Forward Price EarningsSURG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SURG Per share dataSURG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

SURG's earnings are expected to decrease with -27.94% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-45.58%
EPS Next 3Y-27.94%

More info and screens

0

5. Dividend

5.1 Amount

SURG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SURGEPAYS INC

NASDAQ:SURG (2/21/2025, 8:00:01 PM)

After market: 1.36 -0.01 (-0.73%)

1.37

-0.03 (-2.14%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupTelecommunication Services
GICS IndustryWireless Telecommunication Services
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-10 2025-03-10/amc
Inst Owners10.05%
Inst Owner Change-99.83%
Ins Owners31.04%
Ins Owner Change0.83%
Market Cap27.62M
Analysts80
Price Target5.87 (328.47%)
Short Float %3.01%
Short Ratio2.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-496.37%
Min EPS beat(2)-824.37%
Max EPS beat(2)-168.38%
EPS beat(4)0
Avg EPS beat(4)-275.3%
Min EPS beat(4)-824.37%
Max EPS beat(4)-54.2%
EPS beat(8)4
Avg EPS beat(8)68.32%
EPS beat(12)4
Avg EPS beat(12)-231.85%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-24.15%
Min Revenue beat(2)-45.89%
Max Revenue beat(2)-2.4%
Revenue beat(4)1
Avg Revenue beat(4)-11.6%
Min Revenue beat(4)-45.89%
Max Revenue beat(4)7.36%
Revenue beat(8)1
Avg Revenue beat(8)-10.72%
Revenue beat(12)3
Avg Revenue beat(12)-8.51%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.17%
EPS NQ rev (1m)-10%
EPS NQ rev (3m)-237.5%
EPS NY rev (1m)-10.99%
EPS NY rev (3m)-43.67%
Revenue NQ rev (1m)-8.1%
Revenue NQ rev (3m)-75.05%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.33
P/FCF N/A
P/OCF N/A
P/B 0.83
P/tB 1.01
EV/EBITDA N/A
EPS(TTM)-1.13
EYN/A
EPS(NY)-0.17
Fwd EYN/A
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS4.15
BVpS1.64
TBVpS1.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -55.17%
ROE -69.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 5.2%
FCFM N/A
ROA(3y)-7.37%
ROA(5y)-50.43%
ROE(3y)-107.11%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y78.16%
GM growth 5Y-10.03%
F-Score3
Asset Turnover2.01
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.24
Quick Ratio 4.7
Altman-Z 1.65
F-Score3
WACC7.88%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-177.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-248.98%
EPS Next Y-216.68%
EPS Next 2Y-45.58%
EPS Next 3Y-27.94%
EPS Next 5YN/A
Revenue 1Y (TTM)-40.73%
Revenue growth 3Y36.1%
Revenue growth 5Y55.26%
Sales Q2Q%-86.04%
Revenue Next Year-57%
Revenue Next 2Y-17.14%
Revenue Next 3Y6.49%
Revenue Next 5YN/A
EBIT growth 1Y-204.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-189.44%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y7.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.33%
OCF growth 3YN/A
OCF growth 5YN/A